Whales with a lot of money to spend have taken a noticeably bearish stance on Eli Lilly.
Looking at options history for Eli Lilly LLY we detected 13 trades.
If we consider the specifics of each trade, it is accurate to state that 38% of the investors opened trades with bullish expectations and 61% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $185,940 and 10, calls, for a total amount of $463,424.
Predicted Price Range
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $500.0 and $700.0 for Eli Lilly, spanning the last three months.
Insights into Volume & Open Interest
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Eli Lilly's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Eli Lilly's substantial trades, within a strike price spectrum from $500.0 to $700.0 over the preceding 30 days.
Eli Lilly Call and Put Volume: 30-Day Overview
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| LLY | CALL | TRADE | BEARISH | 01/16/26 | $600.00 | $143.0K | 181 | 0 |
| LLY | PUT | SWEEP | BULLISH | 01/26/24 | $642.50 | $112.2K | 121 | 201 |
| LLY | CALL | SWEEP | BULLISH | 02/02/24 | $645.00 | $63.8K | 1.8K | 255 |
| LLY | CALL | TRADE | BEARISH | 06/21/24 | $500.00 | $45.0K | 589 | 3 |
| LLY | CALL | TRADE | BULLISH | 02/16/24 | $610.00 | $38.6K | 1.1K | 11 |
About Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
In light of the recent options history for Eli Lilly, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Eli Lilly's Current Market Status
- With a volume of 64,591, the price of LLY is up 0.54% at $633.05.
- RSI indicators hint that the underlying stock may be overbought.
- Next earnings are expected to be released in 13 days.
What Analysts Are Saying About Eli Lilly
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $655.0.
- Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Eli Lilly, targeting a price of $680.
- An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $630.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Eli Lilly, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
